Forward Industries, Inc. (FORD) - 10-K Summary
Business Context and Reporting Period
Company: Forward Industries, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2024 (Fiscal 2024)
Business Overview: A global design, sourcing, and distribution company serving medical and technology customers. Operations are divided into two segments: OEM Distribution (carrying cases/accessories) and Design (hardware/software engineering). The Company ceased operations of its retail distribution segment in July 2023, classifying it as discontinued operations.
Key Financial Metrics
| Metric | Fiscal 2024 | Fiscal 2023 |
|---|---|---|
| Net Revenues | $30.20 million | $36.69 million |
| Gross Profit | $6.21 million | $8.36 million |
| Gross Margin | 20.6% | 22.8% |
| Operating Loss | ($1.93 million) | $0.16 million (Income) |
| Net Loss (Continuing Ops) | ($1.95 million) | $0.16 million (Income) |
| Net Loss (Total) | ($1.95 million) | ($3.74 million) |
| Cash Balance (Sep 30, 2024) | $3.02 million | $3.18 million |
| Working Capital | $0.27 million | $0.03 million |
| Debt (Note to Forward China) | $0.60 million | $1.10 million |
| Accounts Payable (Forward China) | $7.23 million | $8.25 million |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 17.7% to $30.20 million, driven by a 27.1% drop in OEM Distribution revenue and a 11.9% drop in Design revenue.
- OEM Segment: Diabetic product revenues fell 33.2% due to the loss of a major customer in March 2023 and shifting consumer demand toward devices not requiring carrying cases.
- Design Segment: Revenues declined primarily due to a $2.6 million decrease from one major customer. Operating income collapsed from $2.18 million to $0.03 million due to lower utilization rates and a $200,000 goodwill impairment charge.
- Profitability: The Company swung from a $0.16 million operating income in Fiscal 2023 to a $1.93 million operating loss in Fiscal 2024.
- Discontinued Operations: The retail segment was fully liquidated by September 30, 2024. Fiscal 2023 included a significant loss from discontinued operations ($3.90 million), whereas Fiscal 2024 impact was negligible ($0.003 million).
Guidance, Outlook, and Risks
- Going Concern Warning: The independent auditor has raised substantial doubt about the Company's ability to continue as a going concern. Management forecasts that existing cash and working capital will not be sufficient to meet liquidity needs through December 31, 2025.
- Customer Concentration Risk: In December 2024, the largest design customer (25.2% of Fiscal 2024 revenue) notified the Company of plans to discontinue an insulin patch program, expected to cause a material revenue decrease starting in Q2 Fiscal 2025.
- Liquidity Strategy: The Company is pursuing cost reductions (including workforce reductions), seeking payment term flexibility from Forward China, and exploring debt or equity financing. There is no assurance financing will be available.
- Related Party Dependence: The Company relies exclusively on Forward China (owned by the CEO) for sourcing. Forward China holds a $600,000 note due June 30, 2025, and is owed $7.23 million in accounts payable. An agreement limits collection of pre-existing payables to $500,000 per 12-month period.
- Nasdaq Compliance: The Company regained compliance with Nasdaq listing standards in July 2024 via a reverse stock split and debt-to-equity conversion but remains under a "Panel Monitor" until July 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $2.3 million cash balance (as of Nov 30, 2024) against the projected revenue loss from the insulin patch program discontinuation.
- Related Party Solvency: Assess the risk associated with the $7.23 million payable to Forward China and the $600,000 note due in June 2025, given the CEO's ownership of the creditor.
- Customer Diversification: Evaluate the Company's progress in replacing the lost revenue from the largest design customer and the major diabetic OEM customer lost in 2023.
- Goodwill Impairment: Review the assumptions used in the $200,000 goodwill impairment for the Kablooe reporting unit and the potential for future impairments.
- Financing Plans: Confirm if any new debt or equity financing agreements have been secured to bridge the liquidity gap identified in the going concern assessment.